AI-designed inhibitor targets key enzyme to fight prostate cancer drug resistance
Tuesday, July 1, 2025 - 15:47
in Health & Medicine
Prostate cancer is one of the most common malignancies in men globally. Hormonal therapies targeting the androgen–androgen receptor axis have significantly delayed disease progression. However, drug resistance remains inevitable, and new therapeutic targets and strategies are required to overcome androgen receptor pathway inhibitor (ARPI) resistance.